Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of EDP 514 in Viremic Chronic Hepatitis B Virus Infected Patients Not Currently on Treatment

Next Previous
Trial Profile

A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of EDP 514 in Viremic Chronic Hepatitis B Virus Infected Patients Not Currently on Treatment

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EDP 514 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Enanta Pharmaceuticals

Most Recent Events

  • 26 Jun 2022 Results assessing safety, pharmacokinetic (PK) and antiviral activity from a phase 1b study of multiple ascending doses of EDP-514 in viremic, chronic hepatitis B patients, presented at The International Liver Congress 2022.
  • 08 Jun 2022 According to an Enanta Pharmaceuticals media release, data from this study will be presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2022.
  • 06 Jan 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top